S'abonner

Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial - 24/02/22

Doi : 10.1016/S1473-3099(21)00327-3 
Stephen E Goldstone, MD a, , Anna R Giuliano, PhD b, Joel M Palefsky, MD c, Eduardo Lazcano-Ponce, MD d, Mary E Penny, MD e, Robinson E Cabello, MD f, Edson D Moreira, MD g, Ezio Baraldi, MBChB h, Heiko Jessen, MD i, Alex Ferenczy, MD j, Robert Kurman, MD k, Brigitte M Ronnett, MD k, Mark H Stoler, MD l, Oliver Bautista, PhD m, Rituparna Das, MD m, Thomas Group, MS m, Alain Luxembourg, MD m, Hao Jin Zhou, PhD n, o, Alfred Saah, MD m
a Icahn School of Medicine at Mount Sinai, New York, NY, USA 
b Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA 
c Department of Medicine, University of California at San Francisco, CA, USA 
d Instituto Nacional de Salud Pública, Santa María Ahuacatitlán, Cuernavaca, México 
e Instituto de Investigación Nutricional, Lima, Peru 
f Asociación Via Libre, Lima, Peru 
g Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil 
h Trialtech Research Institute, Pretoria, South Africa 
i Praxis Jessen2 + Kollegen, Berlin, Germany 
j McGill University Health Center, Montreal, QC, Canada 
k Department of Gynecology and Obstetrics and Department of Pathology Johns Hopkins University, Baltimore, MD, USA 
l Department of Pathology, University of Virginia, Charlottesville, VA, USA 
m Merck & Co, Kenilworth, NJ, USA 
n MSD China, Beijing, China 
o Sun Yat-sen University, Guangzhou, China 

* Correspondence to: Dr Stephen E Goldstone, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Icahn School of Medicine at Mount Sinai New York NY 10029 USA

Summary

Background

The quadrivalent human papillomavirus (HPV) vaccine was shown to prevent infections and lesions related to HPV6, 11, 16, and 18 in a randomised, placebo-controlled study in men aged 16–26 years. We assessed the incidences of external genital warts related to HPV6 or 11, and external genital lesions and anal dysplasia related to HPV6, 11, 16, or 18, over 10 years of follow-up.

Methods

The 3-year base study was an international, multicentre, double-blind, randomised, placebo-controlled trial done at 71 sites in 18 countries. Eligible participants were heterosexual men (aged 16–23 years) or men who have sex with men (MSM; aged 16–26 years). Men who had clinically detectable anogenital warts or genital lesions at screening that were suggestive of infection with non-HPV sexually transmitted diseases, or who had a history of such findings, were excluded. Eligible participants were randomly assigned (1:1) to receive three doses of either quadrivalent HPV vaccine or placebo on day 1, month 2, and month 6, administered as a 0·5-mL injection into the deltoid muscle. The 7-year, open-label, long-term follow-up extension study was done at 46 centres in 16 countries. Participants who received one or more doses of the quadrivalent HPV vaccine in the base study were eligible for enrolment into the long-term follow-up study (early vaccination group). Placebo recipients were offered the three-dose quadrivalent HPV vaccine at the end of the base study; those who received one or more quadrivalent HPV vaccine doses were eligible for enrolment into the long-term follow-up study (catch-up vaccination group). The primary efficacy endpoints were the incidence of external genital warts related to HPV6 or 11 and the incidence of external genital lesions related to HPV6, 11, 16, or 18 in all participants and the incidence of anal intraepithelial neoplasia (including anal warts and flat lesions) or anal cancer related to HPV6, 11, 16, or 18 in MSM only. The primary efficacy analysis was done in the per-protocol population for the early vaccination group, which included participants who received all three vaccine doses, were seronegative at day 1 and PCR-negative from day 1 through month 7 of the base study for the HPV type being analysed, had no protocol violations that could affect evaluation of vaccine efficacy, and had attended at least one visit during the long-term follow-up study. For the catch-up vaccination group, efficacy was assessed in the modified intention-to-treat population, which included participants who had received at least one vaccine dose, were seronegative and PCR-negative for HPV types analysed from day 1 of the base study to the final follow-up visit before receiving the quadrivalent HPV vaccine, and had at least one long-term follow-up visit. Safety was assessed in all randomised participants who received at least one vaccine dose. This study is registered with ClinicalTrials.gov, NCT00090285.

Findings

Between Aug 10, 2010, and April 3, 2017, 1803 participants were enrolled in the long-term follow-up study, of whom 936 (827 heterosexual men and 109 MSM) were included in the early vaccination group and 867 (739 heterosexual men and 128 MSM) were included in the catch-up vaccination group. Participants in the early vaccination group were followed up for a median of 9·5 years (range 0·1–11·5) after receiving the third dose of the quadrivalent HPV vaccine, and participants in the catch-up vaccination group were followed up for a median of 4·7 years (0·0–6·6) after receiving the third dose. In early vaccine group participants during long-term follow-up compared with the placebo group in the base study, the incidence per 10 000 person-years of external genital warts related to HPV6 or 11 was 0·0 (95% CI 0·0–8·7) versus 137·3 (83·9–212·1), of external genital lesions related to HPV6, 11, 16, or 18 was 0·0 (0·0–7·7) versus 140·4 (89·0–210·7), and of anal intraepithelial neoplasia or anal cancer related to HPV6, 11, 16, or 18 in MSM only was 20·5 (0·5–114·4) versus 906·2 (553·5–1399·5). Compared with during the base study (ie, before quadrivalent HPV vaccine administration), during the long-term follow-up period, participants in the catch-up vaccination group had no new reported cases of external genital warts related to HPV6 or 11 (149·6 cases per 10 000 person-years [95% CI 101·6–212·3] vs 0 cases per 10 000 person-years [0·0–13·5]) or external genital lesions related to HPV6, 11, 16, or 18 (155·1 cases per 10 000 person-years [108·0–215·7] vs 0 cases per 10 000 person-years [0·0–10·2]), and a lower incidence of anal intraepithelial neoplasia or anal cancer related to HPV6, 11, 16, or 18 (886·0 cases per 10 000 person-years [583·9–1289·1] vs 101·3 cases per 10 000 person-years [32·9–236·3]). No vaccine-related serious adverse events were reported.

Interpretation

The quadrivalent HPV vaccine provides durable protection against anogenital disease related to HPV6, 11, 16, and 18. The results support quadrivalent HPV vaccination in men, including catch-up vaccination.

Funding

Merck Sharp & Dohme.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  The Author(s). Published by Elsevier Ltd.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 3

P. 413-425 - mars 2022 Retour au numéro
Article précédent Article précédent
  • Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
  • Minggui Wang, Michelle Earley, Liang Chen, Blake M Hanson, Yunsong Yu, Zhengyin Liu, Soraya Salcedo, Eric Cober, Lanjuan Li, Souha S Kanj, Hainv Gao, Jose M Munita, Karen Ordoñez, Greg Weston, Michael J Satlin, Sandra L Valderrama-Beltrán, Kalisvar Marimuthu, Martin E Stryjewski, Lauren Komarow, Courtney Luterbach, Steve H Marshall, Susan D Rudin, Claudia Manca, David L Paterson, Jinnethe Reyes, Maria V Villegas, Scott Evans, Carol Hill, Rebekka Arias, Keri Baum, Bettina C Fries, Yohei Doi, Robin Patel, Barry N Kreiswirth, Robert A Bonomo, Henry F Chambers, Vance G Fowler, Cesar A Arias, David van Duin, Multi-Drug Resistant Organism Network Investigators, Lilian M Abbo, Deverick J Anderson, Rebekka Arias, Cesar A Arias, Keri Baum, Robert A Bonomo, Henry F Chambers, Liang Chen, Kean Lee Chew, Eric Cober, Heather R Cross, Partha Pratim De, Samit Desai, Sorabh Dhar, Valentina Di Castelnuovo, Lorena Diaz, AN Q Dinh, Yohei Doi, Michelle Earley, Brandon Eilertson, Beth Evans, Scott Evans, Vance G Fowler Jr, Bettina C Fries, Hainv Gao, Julia Garcia-Diaz, Omai B Garner, Kerryl Greenwood-Quaintance, Blake Hanson, Erica Herc, Carol Hill, Jesse T Jacob, Jianping Jiang, Robert C Kalayjian, Souha S Kanj, Keith S Kaye, Angela Kim, Lauren Komarow, Barry N Kreiswirth, Courtney Lauterbach, Lanjuan Li, Zhengyin Liu, Claudia Manca, Kalisvar Marimuthu, Steven H Marshall, Todd McCarty, Jose Munita, Oon Tek Ng, Jose Millan Oñate Gutierrez, Karen Ordoñez, Robin Patel, David L Paterson, Anton Peleg, Jinnethe Reyes, Susan D Rudin, Robert A Salata, Soraya Salcedo, Michael J Satlin, Suzannah Schmidt-Malan, Nares Smitasin, Maria Spencer, Martin Stryjewski, Jiachun Su, Paul Ananth Tambyah, Sandra Valderrama, David van Duin, Maria Virginia Villegas Botero, Minggui Wang, Mary Waters, Greg Weston, Darren Wong, Glenn Wortmann, Yang Yang, Yunsong Yu, Fujie Zhang
| Article suivant Article suivant
  • Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method
  • Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti, Jigeeshu V Divatia, Ravi Jain, Camilla Rodrigues, Victor D Rosenthal, Waleed Alhazzani, Yaseen M Arabi, Jan Bakker, Matteo Bassetti, Jan De Waele, George Dimopoulos, Bin Du, Sharon Einav, Laura Evans, Simon Finfer, Claude Guérin, Naomi E Hammond, Samir Jaber, Ruth M Kleinpell, Younsuck Koh, Marin Kollef, Mitchell M Levy, Flavia R Machado, Jordi Mancebo, Ignacio Martin-Loeches, Mervyn Mer, Michael S Niederman, Paolo Pelosi, Anders Perner, John V Peter, Jason Phua, Lise Piquilloud, Mathias W Pletz, Andrew Rhodes, Marcus J Schultz, Mervyn Singer, Jéan-François Timsit, Balasubramanian Venkatesh, Jean-Louis Vincent, Tobias Welte, Sheila N Myatra

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.